文献速递耳科与耳神经头颈外科

前庭神经鞘瘤中的外淋巴信号改变:进展性听力损失的潜在生物标志物?

Perilymphatic Signal Changes in Vestibular Schwannoma: A Potential Biomarker of Progressive Hearing Loss?
PubMed 文献 · Otolaryngol Head Neck Surg · 2025-03-19

该回顾性病例对照研究纳入172例前庭神经鞘瘤患者与61例无耳科症状对照,评估梯度回波T2加权3T磁共振上前庭池及耳蜗外淋巴信号强度比与临床症状的关系。结果显示肿瘤患者前庭池与脑脊液信号强度比及耳蜗与脑脊液信号强度比均较对照显著降低,且与肿瘤体积呈显著负相关;前庭池信号强度比与进展性听力损失显著相关。作者认为外淋巴信号改变可能是前庭神经鞘瘤听力损害的有前景的无创生物标志物。

要点

  • 前庭神经鞘瘤患者前庭池与脑脊液信号强度比(0.716±0.297)较对照(1.06±0.21)显著降低,P=.004。
  • 耳蜗与脑脊液信号强度比在肿瘤患者为0.66±0.199,较对照0.903±0.011显著降低,P=.004。
  • 前庭池及耳蜗信号强度比均与肿瘤体积呈显著负相关(P<.001)。

核心结论

  • 前庭池及耳蜗外淋巴信号强度改变似乎可作为前庭神经鞘瘤听力损害的有前景的无创生物标志物。

研究设计与样本

  • 回顾性病例对照研究,纳入2008年至2016年在法国斯特拉斯堡图像引导手术研究所接受磁共振成像的前庭神经鞘瘤患者172例,对照组为61例无既往或现存耳科症状者。
  • 根据内听道阻塞程度将前庭神经鞘瘤分为三组,比较前庭池与脑脊液及耳蜗与脑脊液的信号强度比与临床数据的关系。

主要发现

  • 前庭神经鞘瘤患者前庭池与脑脊液信号强度比为0.716±0.297,低于对照组的1.06±0.21,P=.004。
  • 前庭神经鞘瘤患者耳蜗与脑脊液信号强度比为0.66±0.199,低于对照组的0.903±0.011,P=.004。
  • 前庭池与脑脊液信号强度比及耳蜗与脑脊液信号强度比均与肿瘤体积呈显著负相关(P<.001)。
  • 在所有研究的症状中,经脑脊液归一化的前庭池信号强度比与进展性听力损失显著相关(P=.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vestibular schwannomas influence the magnetic resonance (MR) signal intensity (SI) in the vestibular cistern and cochlear perilymph. The aim of this study is to evaluate the relationship between perilymphatic signal changes on gradient-echo T2-weighted 3 T MR sequence and the clinical symptoms. STUDY DESIGN: Retrospective case-control study. SETTING: The study was conducted at the Institute of Image-Guided Surgery in Strasbourg, France. METHODS: Patients with vestibular schwannoma who underwent magnetic resonance imaging at our institution between 2008 and 2016 were retrospectively reviewed. A control group consisted of individuals without past or present otological symptoms. The vestibular schwannomas were divided into three groups, based on the degree of internal auditory canal obstruction. The SI ratios of the vestibular cistern to cerebrospinal fluid (CSF) and cochlea to CSF were compared with clinical data. RESULTS: We included 172 patients with vestibular schwannoma and 61 controls. Vestibular schwannoma was associated with a significant decrease of the SI ratio of the vestibular cistern to CSF (0.716 ± 0.297 vs 1.06 ± 0.21, P = .004) and cochlea to CSF (0.66 ± 0.199 vs 0.903 ± 0.011, P = .004) compared to controls, with significant negative correlation between both the SI ratios of the vestibular cistern and cochlea to CSF with tumor volume (P < .001). Among all the symptoms studied, the SI ratio of the cistern normalized by CSF was significantly associated with progressive hearing loss (P = .003). CONCLUSION: Perilymphatic vestibular cistern and cochlear SI changes appear to be a promising noninvasive biomarker for hearing impairment in vestibular schwannoma.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Péporté ARJ, Gallix B, Venkatasamy A, et al. Perilymphatic Signal Changes in Vestibular Schwannoma: A Potential Biomarker of Progressive Hearing Loss? Otolaryngol Head Neck Surg. 2025. PMID: 40105466. doi:10.1002/ohn.1228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。